Overview

The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain "BETA"

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
0
Participant gender:
All
Summary
The main purpose of the trial is to identify biomarkers from the blood as well as electrophysiologic and morphometric features (chemical, electrophysiologic and ultrasound biomarkers) that reflect the intensity of pain and/or foretell the efficacy of pharmacological (non-surgical) treatment in patients with acute low back pain.
Phase:
Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Semmelweis University
Collaborators:
MEDITOP Pharmaceutical LTD, Hungary
National Research Develpment and Innovation Fund, Hungary
Treatments:
Tolperisone
Criteria
Inclusion Criteria:

- Healthy pain-free volunteers (n=30) outside of the randomized study, will participate
to establish normal values of blood biomarkers.

Exclusion Criteria:

- pain, inflammation,